IBRX Stock Analysis: Immunitybio | NASDAQ

Immunotherapy, Cytokine Proteins, Cell Therapy, Vaccine Vectors

Total Rating 39

Safety 37

Buy Signal -0.15

Biotechnology
Industry Rotation: +11.4

Market Cap: 9.46B
Avg Turnover: 105M

Risk 3d forecast

Volatility114%

VaR 5^th Pctl17.5%

VaR vs Median-6.60%

Reward TTM

Sharpe Ratio1.52

Rel. Str. IBD93

Rel. Str. Peer Group76.8 pctl

Character TTM

Beta2.025

Beta Downside1.691

Hurst Exponent0.575

Choppyness64.1%

Drawdowns 3y

Max DD79.34%

CAGR/Max DD0.29

CAGR/Mean DD0.52

EPS (Earnings per Share)

Last SUE: 0.38
Qual. Beats: 0

Revenue

Rev. CAGR: 1149.88%
Rev. Trend: 95.9%

Last SUE: 0.53
Qual. Beats: 0

Warnings

Negative Equity With Losses

Strong Share Dilution

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Below Sma 200d

Tailwinds

Rs Leader

Seasonality 11.3 years of data, until 10/2026

Jan +2.8% 0

Feb +5.4% 9

Mar -15.2% 21

Apr +0.3% 0

May +3.3% 9

Jun +2.5% 9

Jul -5.6% 9

Aug +0.0% 0

Sep +1.0% 0

Oct -6.0% 14

Nov +11.5% 64

Dec -7.9% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: IBRX Immunitybio

ImmunityBio, Inc. (IBRX) is a San Diego-based biotechnology company developing next-generation immunotherapies designed to activate the patients immune system to treat cancer and infectious diseases. The companys pipeline is built around multiple technology platforms, including cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Its lead commercial product, Anktiva, is an FDA-approved immunotherapy used in combination with bacillus calmette-guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. The company is also advancing 3M-052, a synthetic TLR7/8 agonist, and operates through collaboration agreements with the National Cancer Institute, Serum Institute of India, and BeOne Medicines Ltd., as well as licensing agreements with 3M Innovative Properties Company and Access to Advanced Health Institute.

As a clinical-stage and commercial biotechnology company, ImmunityBio relies on a high-risk, R&D-intensive business model where revenue is dependent on successful commercialization of approved therapies and long-term value is driven by clinical trial outcomes and regulatory milestones. Immunotherapy is a high-growth segment within oncology, where durable immune responses can potentially offer longer-lasting treatment effects compared to traditional chemotherapy.

Headlines to Watch Out For

Anktiva NMIBC FDA approval drives initial commercial launch revenue
NCI and BeiGene partnerships expand immunotherapy pipeline development
Cash burn requires capital raises to fund continued R&D and trials

Piotroski VR-10 (Strict) 1.0

Net Income: -992.4m TTM > 0 and > 6% of Revenue
FCF/TA: -1.51 > 0.02 and ΔFCF/TA -70.83 > 1.0
NWC/Revenue: 218.5% < 20% (prev 278.2%; Δ -59.75% < -1%)
CFO/TA -0.45 > 3% & CFO -281.1m > Net Income -992.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.72 > 1.5 & < 3
Outstanding Shares: last quarter (1.05b) vs 12m ago 18.22% < -2%
Gross Margin: 94.63% > 18% (prev 92.08%; Δ 2.55% > 0.5%)
Asset Turnover: 32.17% > 50% (prev 14.08%; Δ 18.10% > 0%)
Interest Coverage Ratio: -10.92 > 6 (EBIT TTM -909.3m / Interest Expense TTM 83.3m)

Altman Z'' -15.00

A: 0.58 (Total Current Assets 439.0m - Total Current Liabilities 76.7m) / Total Assets 628.5m
B: -7.30 (Retained Earnings -4.59b / Total Assets 628.5m)
C: -1.76 (EBIT TTM -909.3m / Avg Total Assets 515.3m)
D: -0.63 (Book Value of Equity -1.05b / Total Liabilities 1.67b)
Altman-Z'' = -32.54 = D

Beneish M -1.89

DSRI: 0.82 (Receivables 53.5m/22.3m, Revenue 165.8m/56.6m)
GMI: 0.97 (GM 92.08% / 94.63%)
AQI: 1.09 (AQ_t 0.07 / AQ_t-1 0.06)
SGI: 2.93 (Revenue 165.8m / 56.6m)
TATA: -1.13 (NI -992.4m - CFO -281.1m) / TA 628.5m)
Beneish M = -1.89 (Cap -4..+1) = B

What is the price of IBRX shares?

As of November 11, 2026, the stock is trading at USD 6.75 with a total of 20,007,921 shares traded. Over the past week, the price has changed by -18.64%, over one month by -33.35%, over three months by -9.95% and over the past year by +212.27%.

Current recommended Stop Loss: 5.80 (which is 14.1% or 1.2 ATR below the current price).

Is IBRX a buy, sell or hold?

Immunitybio has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy IBRX.

StrongBuy: 3
Buy: 1
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IBRX price?

Analysts Target Price	14.3	111.1%

Immunitybio (IBRX) - Fundamental Data Overview as of 06 November 2026

Market Cap USD = 9.46b (9.46b USD * 1.0 USD.USD)
P/E Forward = 83.3333
P/S = 57.0856
Revenue TTM = 165.8m USD
EBIT TTM = -909.3m USD
EBITDA TTM = -892.7m USD
Long Term Debt = 774.4m USD (from longTermDebt, last quarter)
Short Term Debt = 7.51m USD (from shortTermDebt, last quarter)
Debt = 851.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 38.7m
Net Debt = 494.4m USD (calculated: Debt 851.8m - CCE 357.4m)
Enterprise Value = 9.96b USD (9.46b + Debt 851.8m - CCE 357.4m)
Interest Coverage Ratio = -10.92 (Ebit TTM -909.3m / Interest Expense TTM 83.3m)
EV/FCF = -10.50x (Enterprise Value 9.96b / FCF TTM -948.9m)
FCF Yield = -9.53% (FCF TTM -948.9m / Enterprise Value 9.96b)
FCF Margin = -572.3% (FCF TTM -948.9m / Revenue TTM 165.8m)
Net Margin = -598.6% (Net Income TTM -992.4m / Revenue TTM 165.8m)
Gross Margin = 94.63% ((Revenue TTM 165.8m - Cost of Revenue TTM 8.91m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 15.85 (Enterprise Value 9.96b / Total Assets 628.5m)
Interest Expense / Debt = 9.77% (Interest Expense 83.3m / Debt 851.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -718.4m (EBIT -909.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.95 (Total Current Assets 439.0m / Total Current Liabilities 88.7m)
Debt / Equity = -0.81 (negative equity) (Debt 851.8m / totalStockholderEquity, last quarter -1.05b)
Debt / EBITDA = -0.55 (negative EBITDA) (Net Debt 494.4m / EBITDA -892.7m)
Debt / FCF = -0.52 (negative FCF - burning cash) (Net Debt 494.4m / FCF TTM -948.9m)
Total Stockholder Equity = -735.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -192.6% (out of range, set to none)
RoE = 135.0% (negative equity) (Net Income TTM -992.4m / Total Stockholder Equity -735.1m)
RoCE = -2.32k% (out of range, set to none) (EBIT -909.3m / Capital Employed (Equity -735.1m + L.T.Debt 774.4m))
RoIC = -130.4% (out of range, set to none) (NOPAT -718.4m / Invested Capital 551.0m)
WACC = 12.04% (E(9.46b)/V(10.3b) * Re(12.43%) + D(851.8m)/V(10.3b) * Rd(9.77%) * (1-Tc(0.21)))
Discount Rate = 12.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.33 | Cagr: 21.88%
[DCF] Fair Price = unknown (Cash Flow -948.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.38 | # QB: 0
Revenue Correlation: 95.91 | Revenue CAGR: 1.15k% | SUE: 0.53 | # QB: 0
EPS current Year (2026-12-31): EPS=-0.92 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-140.8% | GrowthRev=+100.0%
EPS next Year (2027-12-31): EPS=-0.07 | Chg30d=+42.15% | Revisions=+25% | GrowthEPS=+92.0% | GrowthRev=+108.3%
[Analyst] Revisions Ratio: +17% (up=2, down=1)